Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark's US subsidiary is set to launch Leucovorin Calcium for Injection USP, 350 mg/vial in single-dose vial format in the American market. The product is widely used in cancer care, mainly as a rescue therapy after high-dose methotrexate and to boost the effect of 5-FU in colorectal cancer treatment. The launch was announced through a press release dated December 11, 2025. This adds another oncology-support product to Glenmark's growing US generics portfolio.
Strengthens Glenmark's US injectables pipeline and supports steady revenue contribution from the US business. The financial impact of a single generic launch is typically modest but signals continued portfolio expansion in a key market.